Speaker Profile

M.D., DPHIL, CEO, Arctoris Ltd

Biography
Martin-Immanuel Bittner is the CEO of Arctoris, the drug discovery platform company that he co-founded in Oxford in 2016. Martin graduated as a medical doctor from the University of Freiburg in Germany, followed by his DPhil in Oncology as a Rhodes scholar at the University of Oxford. He has extensive research experience covering both clinical trials and preclinical drug discovery and is an active member of several leading cancer research organisations, including EACR, AACR, and ESTRO. In recognition of his research achievements, he was elected a member of the Young Academy of the German National Academy of Sciences and of Sigma Xi.


 Session Abstract – PMWC 2022 Silicon Valley


  • Hope or Hype? The Role of ML in Drug Discovery and Development (PANEL)
    Session Chair: Ansuman Satpathy, Stanford University
    - Marcel Hop, Genentech
    - Noam Solomon, ImmunAI
    - Stacie Calad-Thomson, BioSymetrics
  • Advancing Research and Drug Discovery with UK Biobank
    Session Chair: Asha Collins, DNAnexus
    - Mark Effingham, UK Biobank
  • AI in Small Molecule Design and Screening
    Session Chair: Alex Zhavoronkov, Insilico Medicine
    - Najat Khan, Johnson & Johnson
    - Martin Emanuel Bittner, Arctoris
  • AI/ML in Clinical Trial Design, Patient Selection and Prediction of Outcomes
    Session Chair: Peter Lipsky, Ampel Bio
    - Mika Newton, xCures, Inc.
    - Mark Smith, MedStar Health
    - William Oh, Sema4
  • Emerging Data-driven Clinical Trials
    Session Chair: Adrian Lee, UPMC
    - Laura Esserman, UCSF
    - Derek Angus, UPMC
  • Generating Novel Insights through AI and Multimodal Analysis
    - Philippe Menu, SOPHiA GENETICS
  • Pfize's Data and Analytics Efforts
    - Susie Stephens, Pfizer
  • PMWC 2022 Showcase
    - Kevin Cho, Envisagenics, Inc.
    - Poojitha Ojamies, Novartis